28.04
+0.38(+1.37%)
Currency In USD
| Previous Close | 27.66 |
| Open | 28.22 |
| Day High | 28.4 |
| Day Low | 27.82 |
| 52-Week High | 60.37 |
| 52-Week Low | 25.81 |
| Volume | 344,711 |
| Average Volume | 1.75M |
| Market Cap | 2.65B |
| PE | -4.81 |
| EPS | -5.83 |
| Moving Average 50 Days | 34.42 |
| Moving Average 200 Days | 41.03 |
| Change | 0.38 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $242.1 as of July 30, 2025 at a share price of $28.04. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $361.34 as of July 30, 2025 at a share price of $28.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
GlobeNewswire Inc.
2 hours ago
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today
Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
GlobeNewswire Inc.
Jul 14, 2025 12:00 PM GMT
First and only medicine approved by Health Canada for patients as young as 6-months of age with HoFH, an ultrarare, inherited form of high cholesterolTORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopha
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
GlobeNewswire Inc.
Jul 11, 2025 8:30 PM GMT
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable FDA clinical reviews acknowledged that the clinical data are robust and biomarker data are supportive NOVATO, Calif.,